Preoperative optimization of patients with liver disease

Current Opinion in Anaesthesiology

Volumn 18, Issue 3, 2005, Pages 325-331

  De Wolf, Andre M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Liver transplantation; Preoperative evaluation; Preoperative optimization

Indexed keywords

ALBUMIN; DOBUTAMINE; LACTULOSE; METRONIDAZOLE; NEOMYCIN; NORADRENALIN; PARACETAMOL; PROSTACYCLIN; VASOPRESSIN;

AUTONOMIC NEUROPATHY; HEMODYNAMICS; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HEPATITIS C; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; HYDROTHORAX; KIDNEY BLOOD FLOW; LIVER CANCER; LIVER DISEASE; LIVER FAILURE; LIVER TRANSPLANTATION; LIVING DONOR; MORTALITY; PARACENTESIS; PORTOSYSTEMIC ANASTOMOSIS; PREOPERATIVE CARE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; STRESS ECHOCARDIOGRAPHY; THORACOCENTESIS;

EID: 20444417432     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aco.0000169242.03754.cc     Document Type: Review

References (69)

1. Plotkin JS, Benitez RM, Kuo PC, et al. Dobutamine stress echocardiography for preoperative cardiac risk stratification in patients undergoing orthotopic liver transplantation. Liver Transpl Surg 1998; 4:253-257.
2. Zoghbi GJ, Patel AD, Ershadi RE, et al. Usefulness of preoperative stress perfusion imaging in predicting prognosis after liver transplantation. Am J Cardiol 2003; 92:1066-1071.
3. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996; 24:451-459.
4. Donovan CL, Marcovitz PA, Punch JD, et al. Two-dimensional and dobutamine stress echocardiography in the preoperative assessment of patients with endstage liver disease prior to orthotopic liver transplantation. Transplantation 1996; 61:1180-1188.
5. Sampathkumar P, Lerman A, Kim BY, et al. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998; 4:399-403.
6. Axelrod D, Koffron A, DeWolf A, et al. Safety and efficacy of combined orthotopic liver transplantation and coronary artery bypass grafting. Liver Transpl 2004; 10:1386-1390. This paper presents good results of combined coronary artery bypass grafting and liver transplantation.
7. Plotkin JS, Scott VL, Pinna A, et al. Morbidity and mortality in patients with coronary artery disease undergoing orthotopic liver transplantation. Liver Transpl Surg 1996; 2:426-430.
8. Porrett PM, Desai SS, Timmins KJ, et al. Combined orthotopic heart and liver transplantation: the need for exception status listing. Liver Transpl 2004; 10:1539-1544. The authors propose exception-status listing for patients awaiting combined heart and liver transplantation based on their good results.
9. Nardo B, Beltempo P, Bertelli R, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transpl Proc 2004; 36:645-647.
10. Haynes H, Farroni J. Successful combined heart-liver transplantation in a patient with hemochromatosis. Prog Transpl 2004; 14:39-40.
11. Boucek C, Krishnamurthy P, Marsh JW, Lee J. Anesthesia management of orthotopic liver transplantation in a patient with Mustard repair of transposition of great arteries and superior vena caval obstruction. Anesthesiology 2004; 100:183-185. This article describes in detail the very complex management of liver transplantation in an exceptional patient who had a Mustard repair.
12. Therapondos G, Flapan AD, Plevris JN, Hayes PC. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004; 10:1441-1453. Excellent review article discussing cardiac-related issues. There is also a nice summary on PPHTN and hepatopulmonary syndrome.
13. Carey EJ, Douglas DD, Balan V, et al. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: a single-center experience. Liver Transpl 2004; 10:529-533. Although bilirubin concentration and coagulation parameters normalize more slowly in patients undergoing living-donor liver transplantation when compared to cadaveric liver transplantation, the resolution of hepatopulmonary syndrome follows a similar course.
14. Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. Hepatology 2003; 37:192-197.
15. Kim BJ, Lee SC, Park SW, et al. Characteristics and prevalence of intrapulmonary shunt detected by contrast echocardiography with harmonic imaging in liver transplant candidates. Am J Cardiol 2004; 94:525-528. The authors document a very high incidence of intrapulmonary vascular dilatations (80%); this does not necessarily result in hypoxemia and therefore not all these patients have the hepatopulmonary syndrome.
16. Ryu JK, Oh JH. Hepatopulmonary syndrome: angiography and therapeutic embolization. Clin Imag 2003; 27:97-100.
17. Hoeper MM, Krowka MJ, Strassburgh CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461-1468. An excellent review article discussing pulmonary complications of severe liver disease.
18. Mandell MS. Hepatopulmonary syndrome and portopulmonary hypertension in the model for end-stage liver disease (MELD) era. Liver Transpl 2004; 10:S54-S58. A good review article on hepatopulmonary syndrome and PPHTN.
19. Mazzeo AT, Lucanto T, Santamaria LB. Hepatopulmonary syndrome: a concern for the anesthetist? Preoperative evaluation of hypoxemic patients with liver disease. Acta Anaesthesiol Scand 2004; 48:178-186. Another very good review article on hepatopulmonary syndrome.
20. Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52:1355-1362.
21. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401-409.
22. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63:604-606.
23. Kato H, Katori T, Nakamura Y, Kawarasaki H. Moderate-term effect of epoprostenol on severe portopulmonary hypertension. Pediatr Cardiol 2003; 24:50-53.
24. Krowka MJ, Mandell MS, Ramsay MAE, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transpl 2004; 10:174-182. This is an interesting review based on a multicenter database. Unfortunately little new information has emerged from this endeavor; it merely confirms previous observations.
25. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004; 10:945-950. This is the first case report describing the successful use of sildenafil for PPHTN.
26. Clift PF, Townend JN, Bramhall S, Isaac JL. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004; 77:1774-1775. Bosentan, an endothelin antagonist, was administered postoperatively to a patient with moderate-severe pulmonary hypertension in order to reduce PPHTN.
27. Garcia N Jr, Mihas AA. Hepatic hydrothorax. Pathophysiology, diagnosis, and management. J Clin Gastroenterol 2004; 38:52-58. This is an excellent review article discussing hepatic hydrothorax.
28. Moore KP, Wong F, Gines P, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology 2003; 38:258-266.
29. Heuman DM, Abou-assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802-810. Persistent ascites and hyponatremia identify cirrhotic patients with high mortality risk despite low MELD scores.
30. Restuccia T, Ortega R, Guevara M, et al. Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol 2004; 40:140-146. An excellent and well-controlled study indicating that treatment of hepatorenal syndrome with vasopressin before liver transplantation results in the same outcome after liver transplantation as in patients without hepatorenal syndrome.
31. Moreau R. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation. Editorial. J Hepatol 2004; 40:159-161. A brief summary of the important new issues regarding hepatorenal syndrome.
32. Ginės P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362:1819-1827.
33. Rosado B, Kamath PS. Transjugular intrahepatic portosystemic shunts: an update. Liver Transpl 2003; 9:207-217.
34. Madoff DC, Wallace MJ, Ahrar K, Saxon RR. TIPS-related hepatic encephalopathy: management options with novel endovascular techniques. Radio-Graphics 2004; 24:21-37. A fascinating review of what can be accomplished by interventional radiologists.
35. Balata S, Olde Damink SW, Ferguson K, et al. Induced hyperammonemia alters neuropsychology, brain MRI spectroscopy and magnetization transfer in cirrhosis. Hepatology 2003; 37:931-939.
36. Mechtcheriakov S, Graziadei IW, Mattedi M, et al. Incomplete improvement of visuo-motor deficits in patients with minimal hepatic encephalopathy after liver transplantation. Liver Transpl 2004; 10:77-83. Sophisticated neuropsychological tests failed to show an improvement in minimal hepatic encephalopathy in all patients after liver transplantation, suggesting that cirrhosis may cause irreversible changes in the brain in some patients.
37. Rose C, Jalan R. Is minimal hepatic encephalopathy completely reversible following liver transplantation? Editorial. Liver Transpl 2004; 10:84-87. This editorial provides additional discussion on minimal hepatic encephalopathy.
38. Ostapowicz G, Fontana RJ, Schiedt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947-954.
39. Schiødt FV, Davern TJ, Shakil AO, et al. Viral hepatitis-related acute liver failure. Am J Gastroenterol 2003; 98:448-453.
40. Bailey B, Amre DK, Gaudreault P. Fulminant hepatic failure secondary to acetaminophen poisoning: a systematic review and meta-analysis of prognostic criteria determining the need for liver transplantation. Crit Care Med 2003; 31:299-305.
41. Baquerizo A, Anselmo D, Shackleton C, et al. Phosphorus as an early predictive factor in patients with acute liver failure. Transplantation 2003; 75:2007-2014.
42. Chung PY, Sitrin MD, Te HS. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl 2003; 9:248-253.
43. Ng KL, Davidson JS, Bathgate AJ. Serum phosphate is not a reliable early predictor of outcome in paracetamol induced hepatotoxicity. Liver Transpl 2004; 10:158-159. In this letter to the editor, a large retrospective analysis by the Edinburgh group could not confirm that hypophosphatemia was associated with a better spontaneous outcome.
44. Vaquero J, Jordano Q, Lee WM, Blei AT. Serum Protein S-100b in acute liver failure: results of the US acute liver failure study group. Liver Transpl 2003; 9:887-888.
45. Häussinger D. Fulminant liver failure: is living related liver transplantation justified with respect to donor risk? Transpl Proc 2003; 35:920-921.
46. Chan C, Berthiaume F, Math BD, et al. Hepatic tissue engineering for adjunct and temporary liver support: critical technologies. Liver Transpl 2004; 10:1331-1342. An impressive review on the technical and engineering challenges that must be resolved in order to develop the next generation of support devised.
47. Sauer IM, Zeilinger K, Pless G, et al. Extracorporeal liver support based on primary human liver cells and albumin dialysis - treatment of a patient with primary graft non-function. J Hepatol 2003; 39:649-653.
48. Koivusalo AM, Yildirim Y, Vakkuri A, et al. Experience with albumin dialysis in five patients with sever overdoses of paracetamol. Acta Anaesthesiol Scand 2003; 47:1145-1150.
49. Khuroo MS, Khuroo MS, Farahat KLC. Molecular adsorbent recirculating system for acute and acute-on-chronic liver failure: a meta-analysis. Liver Transpl 2004; 10:1099-1106. The meta-analysis revealed only a few trials with a small number of patients, allowing for the possibility of erroneous conclusions.
50. Stange J. Meta-analysis in albumin dialysis: are we really ready for it? Editorial. Liver Transpl 2004; 10:1107-1108. In this editorial, the lack of randomized and controlled trials is emphasized.
51. Sen S, Davies NA, Mookerjee RP, et al. Pathophysiological effects of albumin dialysis in acute-on-chronic liver failure: a randomized controlled study. Liver Transpl 2004; 10:1109-1119. In this particular group of patients, albumin dialysis improved encephalopathy but not blood pressure or renal function.
52. Demetriou AA, Brown RS, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239:660-670. This is the first prospective, randomized, controlled trial of an extracorporeal liver support system. The authors found improved survival in patients with fulminant and subfulminant hepatic failure.
53. Van de Kerkhove MP, Hoekstra R, Chamuleau RAFM, Van Gulik TM. Clinical application of bioartificial liver support systems. Ann Surg 2004; 240:216-230.
54. Abt P, Crawford M, Desai N, et al. Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation 2003; 75:1659-1663.
55. Wilson DJ, Fisher A, Das K, et al. Donors with cardiac arrest: improved organ recovery but no preconditioning benefit in liver allografts. Transplantation 2003; 75:1683-1687.
56. Sugawara Y, Makuuchi M. Advances in adult living donor liver transplantation: a review based on reports from the 10th anniversary of the adult-to-adult living donor liver transplantation meeting in Tokyo. Liver Transpl 2004; 10:715-720. An excellent review of living-donor liver transplantation from Japan, where the first adult-to-adult living related liver transplantation was performed in 1993.
57. Schumann R, Zabala L, Angelis M, et al. Altered hematologic profiles following donor right hepatectomy and implications for perioperative analgesic management. Liver Transpl 2004; 10:363-368. In this small study in eight liver donors, increased international normalized ratio and decreased platelet count were observed for several days after surgery.
58. Siniscalchi A, Begliomini B, De Pietri L, et al. Increased prothrombin time and platelet counts in living donor right hepatectomy: implications for epidural anesthesia. Liver Transpl 2004; 10:1144-1149. A larger study confirming the coagulation abnormalities.
59. Cerutti E, Stratta C, Romagnoli R, et al. Thromboelastogram monitoring in the perioperative period of hepatectomy for adult living liver donation. Liver Transpl 2004; 10:289-294. A very interesting study using different methodology resulting in opposite conclusions from the previous two studies.
60. Russo MW. Evaluating the potential living liver donor. Editorial. Liver Transpl 2004; 10:1097-1098. This editorial proposed the use of regularly updated clinical practice guidelines to evaluate living liver donors.
61. Akabayashi A, Slingsby BT, Fujita M. The first donor death after living-related liver transplantation in Japan. Transplantation 2004; 77:634-639. This case report describes the liver failure after right lobectomy, probably the result of fatty infiltration of the organ (nonalcoholic steatohepatitis or NASH).
62. Hwang S, Lee SG, Jang SJ, et al. The effect of donor weight reduction on hepatic steatosis for living donor liver transplantation. Liver Transpl 2004; 10:721-725. Donor weight reduction reduced the degree of fatty infiltration in nine potential donors from 48.9 to 25.6%.
63. Miller C, Florman S, Kim-Schluger L, et al. Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl 2004; 10:1315-1319. This report gives a detailed description of the events leading to the death in one donor. Surgical stress, relative portal hypertension and the alkaline gastric environment induced by an H2 blocker increased the stomach's susceptibility to clostridia.
64. Tan HP, Madeb R, Kovach SJ, et al. Hypophosphatemia after 95 right-lobe living-donor hepatectomies for liver transplantation is not a significant source of morbidity. Transplantation 2003; 76:1085-1088.
65. Pomposelli JJ, Burns DL. Hypophosphatemia and the live liver donor. Transplantation 2004; 78:305. In this letter to the editor, in response to the previous article, [64], the authors argue in favor of routine administration of phosphorus when hypophosphatemia is present.
66. Lutz JT, Valentin-Gamazo C, Görlinger K, et al. Blood-transfusion requirements and blood salvage in donors undergoing right hepatectomy for living related liver transplantation. Anesth Analg 2003; 96:351-355.
67. McDougall AJ, Davies L, McCaughan GW. Autonomic and peripheral neuropathy in endstage liver disease and following liver transplantation. Muscle Nerve 2003; 28:595-600.
68. Pérez-Peña J, Rincón D, Bañares R, et al. Autonomic neuropathy is associated with hemodynamic instability during human liver transplantation. Transpl Proc 2003; 35:1866-1868.
69. Weissenborn K, Tietge UJ, Bokemeyer M, et al. Liver transplantation improves hepatic myelopathy: evidence by three cases. Gastroenterology 2003; 124:346-351.